View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2013	Mar. 27, 2014	Jun. 28, 2013
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	FY
Trading Symbol	MNOV
Entity Registrant Name	MEDICINOVA INC
Entity Central Index Key	0001226616
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		24,070,943
Entity Public Float			$ 48,678,000

Consolidated Balance Sheets - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 6,700,493	$ 4,010,530
Receivable	6,008,553
Prepaid expense and other current assets	1,673,560	411,592
Total Current Assets	14,382,606	4,422,122
Goodwill	9,600,241	9,600,241
In-process research and development	4,800,000	4,800,000
Investment in joint venture	680,982	667,204
Property and equipment, net	82,414	78,474
Total assets	29,546,243	19,568,041
Current liabilities:
Accounts payable	33,894	491,853
Accrued expenses and other current liabilities	240,148	314,652
Accrued compensation and other related expenses	186,393	228,124
Current deferred revenue		3,163
Total current liabilities	460,435	1,037,792
Long-term deferred rent	9,889
Deferred tax liability	1,956,000	1,956,000
Long-term deferred revenue	1,694,163	1,694,257
Total liabilities	4,120,487	4,688,049
Stockholders' equity:
Preferred stock, $0.01 par value; 3,000,000 shares authorized at December 31, 2013 and 2012; 220,000 shares issued and outstanding at December 31, 2013 and 2012	2,200	2,200
Common stock, $0.001 par value; 100,000,000 shares authorized at December 31, 2013 and 2012; 22,495,443 and 17,407,311 shares issued at December 31, 2013 and 2012, respectively, and 22,495,443 and 17,403,125 shares outstanding at December 31, 2013 and 2012, respectively	22,495	17,407
Additional paid-in capital	326,868,578	312,293,225
Accumulated other comprehensive loss	(80,803)	(67,957)
Treasury stock, at cost; zero shares at December 31, 2013 and 4,186 shares at December 31, 2012		(44,705)
Accumulated deficit	(301,386,714)	(297,320,178)
Total stockholders' equity	25,425,756	14,879,992
Total liabilities and stockholders' equity	$ 29,546,243	$ 19,568,041

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2013	Dec. 31, 2012
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued	220,000	220,000
Preferred stock, shares outstanding	220,000	220,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	22,495,443	17,407,311
Common stock, shares outstanding	22,495,443	17,403,125
Treasury stock, shares	0	4,186

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Revenues:
License revenue	$ 6,000,000
Research and development service revenue	3,257	$ 802,580
Operating expenses:
Research, development and patents	3,365,808	5,013,092
General and administrative	6,657,989	6,734,844
Total operating expenses	10,023,797	11,747,936
Operating loss	(4,020,540)	(10,945,356)
Other expense	(24,518)	(29,605)
Other income	20,565	24,791
Loss before income taxes	(4,024,493)	(10,950,170)
Income taxes	(4,035)	(11,144)
Net loss applicable to common shareholders	$ (4,028,528)	$ (10,961,314)
Basic and diluted net loss per common share	$ (0.19)	$ (0.66)
Shares used to compute basic and diluted net loss per common share	20,697,440	16,522,929
Net loss applicable to common stockholders	$ (4,028,528)	$ (10,961,314)
Other comprehensive loss, net of tax:
Foreign currency translation adjustments	(12,846)	(11,112)
Comprehensive loss	$ (4,041,374)	$ (10,972,426)

Consolidated Statements of Stockholders' Equity - USD ($)	Total	Preferred stock	Common Stock	Additional paid-in capital	Treasury Stock	Accumulated other comprehensive loss	Accumulated deficit
Beginning Balance (in shares) at Dec. 31, 2011		220,000	16,127,615
Beginning Balance at Dec. 31, 2011	$ 23,497,546	$ 2,200	$ 16,128	$ 309,998,251	$ (429,015)	$ (56,845)	$ (286,033,173)
Employee stock-based compensation	709,650			709,650
Option exercises (in shares)			60,000
Option exercises	137,730		$ 60	137,670
Issuance of shares under an employee stock purchase plan	58,619				384,310		(325,691)
Issuance of common stock under a common stock purchase agreement (in shares)			1,219,696
Issuance of common stock under a common stock purchase agreement	1,348,873		$ 1,219	1,347,654
Fair value of warrant issued	100,000			100,000
Net loss	(10,961,314)						(10,961,314)
Foreign currency translation adjustments	(11,112)					(11,112)
Ending Balance (in shares) at Dec. 31, 2012		220,000	17,407,311
Ending Balance at Dec. 31, 2012	14,879,992	$ 2,200	$ 17,407	312,293,225	(44,705)	(67,957)	(297,320,178)
Employee stock-based compensation	$ 1,216,444			1,216,444
Option exercises (in shares)	79,462		79,462
Option exercises	$ 193,951		$ 79	193,872
Issuance of shares under an employee stock purchase plan (in shares)			26,065
Issuance of shares under an employee stock purchase plan	56,487		$ 26	49,764	$ 44,705		(38,008)
Issuance of common stock under a securities purchase agreement (in share)			4,860,939
Issuance of common stock under securities purchase agreements	12,687,125		$ 4,861	12,682,264
Warrant exercises	433,131		$ 122	433,009
Warrant exercises, shares			121,666
Net loss	(4,028,528)						(4,028,528)
Foreign currency translation adjustments	(12,846)					(12,846)
Ending Balance (in shares) at Dec. 31, 2013		220,000	22,495,443
Ending Balance at Dec. 31, 2013	$ 25,425,756	$ 2,200	$ 22,495	$ 326,868,578		$ (80,803)	$ (301,386,714)

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Operating activities:
Net loss	$ (4,028,528)	$ (10,961,314)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash stock-based compensation	1,216,444	709,650
Amortization of Kissei upfront payment	(3,257)	(802,580)
Depreciation and amortization	100,487	69,528
(Gain) loss on disposal of assets	(4,307)	823
Change in value of equity method investment	(13,778)
Changes in assets and liabilities:
Prepaid expenses and other assets	(1,353,334)	266,927
Receivables	(6,008,553)
Accounts payable, income tax payable, accrued expenses and deferred rent	(509,900)	(776,508)
Accrued compensation and related expenses	(41,730)	(370,964)
Net cash used in operating activities	(10,646,456)	(11,864,438)
Investing activities:
Acquisitions of property and equipment	(41,554)	(83,378)
Investment in China Joint Venture		(680,000)
Proceeds from sales of property and equipment	4,800
Net cash used in investing activities	(36,754)	(763,378)
Financing activities:
Proceeds from issuance of common stock and warrants, net of issuance costs	13,363,997	1,486,603
Net proceeds from issuance of Treasury Stock under ESPP	6,697	58,619
Net cash provided by financing activities	13,370,694	1,545,222
Effects of foreign exchange on cash	2,479
Net increase / (decrease) in cash and cash equivalents	2,689,963	(11,082,594)
Cash and cash equivalents, beginning of period	4,010,530	15,093,124
Cash and cash equivalents, end of period	6,700,493	4,010,530
Supplemental disclosure of cash flow information:
Income taxes paid	$ 6,354	$ 10,951

Organization and Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2013

Organization and Summary of Significant Accounting Policies

1. Organization and Summary of Significant Accounting Policies

Organization and Business

The Company was incorporated in the state of Delaware in September 2000 and is a public company. The Company’s common stock is listed in both the U.S. and Japan and trades on The NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange. The Company is a biopharmaceutical company focused on acquiring and developing novel, small molecule therapeutics for the treatment of serious diseases with unmet medical needs with a commercial focus on the U.S. market. The Company is currently focusing its development activities on MN-166, (Ibudilast) for the treatment of neurological disorders, MN-221(Bedoradrine), for the treatment of acute exacerbations of asthma, MN-001(Tipelukast) for the treatment of NASH (nonalcoholic steatohepatitis), and MN-029 (Denibulin) for the treatment of solid tumors.

In December 2013, the Company received notice that a $6.0 million milestone had been achieved under its assignment of rights agreement with Genzyme Corporation, or Genzyme (see Note 2). Prior to 2013, the Company was in the development stage.

As of December 31, 2013, the Company had available cash and cash equivalents of $6.7 million and working capital of $13.9 million.

Principles of Consolidation

The consolidated financial statements include the accounts of MediciNova, Inc. and its wholly-owned subsidiaries MediciNova (Europe) Limited, MediciNova Japan, Inc. and Avigen, Inc. All intercompany transactions and balances are eliminated in consolidation. MediciNova (Europe) Limited was incorporated under the laws of England in 2006. As of December 31, 2013, there have been no significant transactions related to MediciNova (Europe) Limited. MediciNova Japan, Inc. was incorporated in Japan in 2007. On December 18, 2009, the Company acquired Avigen, Inc., a Delaware corporation (Avigen), and it became a wholly-owned subsidiary.

Segment Reporting

The Company operates in a single industry segment – the discovery and development of small molecule therapeutics.

Use of Estimates

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and other highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents at December 31, 2013 consisted of money market funds.

Concentrations and Credit Risk

The Company maintains cash balances at various financial institutions and such balances commonly exceed the $250,000 amount insured by the Federal Deposit Insurance Corporation. The Company also maintains money market funds at various financial institutions which are not federally insured although are invested primarily in U.S. government securities. The Company has not experienced any losses in such accounts and management believes that the Company does not have significant credit risk with respect to such cash and cash equivalents.

Fair Value of Financial Instruments

Financial instruments, including cash and cash equivalents, receivables, accounts payable and accrued liabilities, are carried at cost, which management believes approximates fair value because of the short-term maturity of these instruments.

Goodwill and Purchased Intangibles

The Company records goodwill and other intangible assets based on the fair value of the assets acquired. In determining the fair value of the assets acquired, the Company utilizes extensive accounting estimates and judgments to allocate the purchase price to the fair value of the net tangible and intangible assets acquired. The Company uses the discounted cash flow method to estimate the value of intangible assets acquired.

The Company assesses goodwill and indefinite lived intangible assets for impairment using fair value measurement techniques on an annual basis during the fourth quarter of the year, or more frequently if indicators of impairment exist. The Company periodically re-evaluates the original assumptions and rationale utilized in the establishment of the carrying value and estimated lives of its long-lived assets. The criteria used for these evaluations include management’s estimate of the asset’s continuing ability to generate income from operations and positive cash flows in future periods as well as the strategic significance of any intangible assets in the Company’s business objectives. If assets are considered to be impaired, the impairment recognized is the amount by which the carrying value of the assets exceeds the fair value of the assets.

Research, Development and Patents

Research and development costs are expensed in the period incurred. Research and development costs primarily consist of salaries and related expenses for personnel, facilities and depreciation, research and development supplies, licenses and outside services. Such research and development costs totaled $2.7 million and $4.5 million for the years ended December 31, 2013 and 2012, respectively.

Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. The Company includes all external costs related to the filing of patents on developments in Research, Development and Patents expenses. Such patent-related expenses totaled $0.7 million and $0.5 million for the years ended December 31, 2013 and 2012, respectively.

Stock-Based Compensation

The Company estimates the fair value of stock options using the Black-Scholes option pricing model on the date of grant. The fair value of equity instruments expected to vest are recognized and amortized on a straight-line basis over the requisite service period of the award, which is generally three to four years; however, certain provisions in the Company’s equity compensation plans provide for shorter vesting periods under certain circumstances.

Net Loss Per Share

The Company computes basic net loss per share using the weight average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares and potentially dilutive securities (common share equivalents) outstanding during the period. Common share equivalents outstanding, determined using the treasury stock method, are comprised of shares that may be issued under the Company’s stock option agreements and warrants. Common share equivalents are excluded from the diluted net loss per share calculation because of their anti-dilutive effect. Due to the net income recorded for the fourth quarter of 2013, the Company considered the impact of using the two-class method for presenting net income per share given the participating nature of the Series B Convertible Preferred Stockholders noting the two-class method was not applicable.

Potentially dilutive outstanding securities excluded from diluted net loss per common share because of their anti-dilutive effect:


	December 31,
	2013		2012
Convertible preferred stock, as converted		2,200,000		2,200,000
Stock options		3,217,043		3,328,981
Warrants		3,761,067		3,128,686

Total		9,178,110		8,657,667

Recent Accounting Pronouncements

In December 2011, the Financial Accounting Standards Board (FASB) issued accounting guidance requiring an entity to disclose information about offsetting arrangements and the impact of these arrangements on the Company’s financial position. The guidance is effective for interim and annual periods beginning on or after January 1, 2013. The adoption of this guidance did not have a material impact on the consolidated financial statements.

In February 2013, the Financial Accounting Standards Board issued an accounting standard update to require reclassification adjustments from other comprehensive income to be presented either in the financial statements or in the notes to the financial statements. This accounting standard became effective for the Company beginning in the first quarter of 2013, and its adoption did not have any impact on the financial statements.

In July 2013, the FASB issued guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013, with an option for early adoption. The Company intends to adopt this guidance during the first quarter of 2014, and does not believe the adoption of this standard will have a material impact on the consolidated financial statements.

Revenue Recognition

12 Months Ended

Dec. 31, 2013

Revenue Recognition

2. Revenue Recognition

Revenue Recognition Policy

Revenues consist of milestone payments and research and development services. Milestone payments are recognized as revenue upon achievement of pre-defined scientific events, which require substantive effort, and for which achievement of the milestone was not readily assured at the inception of the agreement. Milestones that do not meet the criteria for accounting under the milestone method because the payments are solely contingent upon the performance of a third party are accounted for as contingent revenue. Research and development services are recognized as research costs are incurred over the period the services are performed. For all other revenue the Company recognizes revenues when all four of the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products and/or services has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured.

Genzyme Corporation

In December 2005, Avigen and Genzyme entered into an Assignment Agreement (Genzyme Agreement) in which Genzyme acquired certain gene therapy intellectual property, programs and other related assets from Avigen in exchange for an initial $12.0 million payment, and Avigen could receive additional development milestone payments, sublicensing fees and royalty payments based on the successful development of products by Genzyme utilizing technologies previously developed by us. Avigen was subsequently acquired by the Company in December 2009 along with Avigen’s rights and obligations under the Genzyme Agreement. If Genzyme fails to diligently pursue the commercialization or marketing of products using the assigned technology, as specified in the Genzyme Agreement, some of the rights assigned could revert back to the Company at a future date.

The development milestones outlined in the Genzyme Agreement do not meet the definition of a substantive milestone obligation under authoritative guidance on revenue recognition for milestone payments, as Genzyme is responsible for the development of the product and there is no further substantive service effort required by the Company. The Company determined that a non-substantive milestone in the Genzyme Agreement had been earned, and license revenue and a receivable of $6.0 million were recorded as no future performance obligation exists. The Company received payment of the amount receivable in January 2014.

Kissei Pharmaceutical Co., Ltd

In October 2011, the Company entered into an agreement with Kissei Pharmaceutical Co., Ltd., or Kissei, to perform research and development services relating to MN-221 in exchange for a non-refundable upfront payment of $2.5 million. Under the terms of the agreement the Company is responsible for all costs to be incurred in the performance of these services. Certain of these research and development services were completed in 2013 and 2012, and the remaining services are expected to be delivered and completed after 2013. The Company assessed the deliverables in accordance with the authoritative guidance and concluded the existence of one deliverable, research and development services. As such, revenue is being recognizing as the research and development services are performed. The amount received from Kissei, net of the amount recorded as revenue, is included on the balance sheet as long-term deferred revenue and will be recognized as revenue as the remaining services are performed. Revenue recorded was $3,000 and $0.8 million in 2013 and 2012, respectively.

Fair Value Measurements

12 Months Ended

Dec. 31, 2013

Fair Value Measurements

3. Fair Value Measurements

Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:


Level 1:		Observable inputs such as quoted prices in active markets;

Level 2:		Inputs are quoted prices for similar items in active markets or inputs are quoted prices for identical or similar items in markets that are not active near the measurement date; and

Level 3:		Unobservable inputs due to little or no market data, which require the reporting entity to develop its own assumptions

Cash equivalents, including money market accounts of $6.0 million and $3.9 million measured at fair value as of December 31, 2013 and 2012, respectively, are classified within Level 1.

Balance Sheet Details

12 Months Ended

Dec. 31, 2013

Balance Sheet Details

4. Balance Sheet Details

Property and Equipment

Property and equipment, net, consist of the following:


	December 31,
	2013			2012
Leasehold improvements	$	16,854		$	170,386
Furniture and equipment		257,945			351,992
Software		238,808			228,397

		513,607			750,775
Less accumulated depreciation and amortization		(431,193	)		(672,301	)

	$	82,414		$	78,474

Depreciation expense	$	36,655		$	33,507

The Company uses the straight-line method to record depreciation expense.

Accrued Expenses

Accrued expenses consist of the following:


	December 31,
	2013		2012
Research and development costs	$	99,846	$	152,046
Professional services fees		38,208		68,102
Other		102,094		94,504

	$	240,148	$	314,652

Related Party Transactions

12 Months Ended

Dec. 31, 2013

Related Party Transactions

5. Related Party Transactions

On October 13, 2011, the Company entered into a services agreement with Kissei to perform two separate studies relating to MN-221 in exchange for $2.5 million paid to the Company in October 2011. The Company is responsible for all costs to be incurred in the performance of these studies. The amount received from Kissei, net of the amount recorded as revenue through December 31, 2013, is included on the balance sheet at December 31, 2013 as deferred revenue and will be recognized as revenue in future periods as the Company performs the remaining services.

On May 9, 2013, the Company entered into a securities purchase agreement with certain accredited investors pursuant to which the Company agreed to sell to the investors 1,158,730 shares of common stock and warrants to purchase an aggregate of 869,047 shares of common stock (the “Private Placement”). The Private Placement closed on May 14, 2013. The Private Placement included issuance of shares of common stock and a warrant to purchase shares of common stock to Fountain Erika LLC (“Fountain Erika”), an entity of which Tatsuo Izumi, a member of the Company’s board of directors at that time, is a principal. The warrant was subsequently amended on May 29, 2013. Fountain Erika’s acquisition of the shares of common stock and a warrant to purchase shares of the Company’s common stock was at an “at the market” price.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

Commitments and Contingencies

12 Months Ended

Dec. 31, 2013

Commitments and Contingencies

6. Commitments and Contingencies

Lease Commitments

The Company subleases its office space under an operating lease with an initial terms of four years and nine months, expiring in November 2017. Rent expense for the years ended December 31, 2013 and 2012 was $259,690 and $286,762, respectively. The difference between the minimum lease payments and the straight-line amount of total rent expense is recorded as deferred rent. Deferred rent at December 31, 2013 and 2012 was $9,889 and zero, respectively.

As of December 31, 2013, the total estimated future annual minimum lease payments under the Company’s non-cancelable building and copier leases for the years ending after December 31, 2013 are as follows:


Years ending December 31:
2014	$	260,213
2015		206,441
2016		167,373
2017		139,608

Total minimum payments	$	773,635

Product Liability

The Company’s business exposes it to liability risks from its potential drug products. A successful product liability claim or series of claims brought against the Company could result in the payment of significant amounts of money and divert management’s attention from running the business. The Company may not be able to maintain insurance on acceptable terms, or the insurance may not provide adequate protection in the case of a product liability claim. To the extent that product liability insurance, if available, does not cover potential claims, the Company would be required to self-insure the risks associated with such claims. The Company believes it carries reasonably adequate insurance for product liability.

License and Research Agreements

The Company has entered into in-licensing agreements with various pharmaceutical companies. Under the terms of these agreements, the Company has received licenses to research, know-how and technology claimed, in certain patents or patent applications. Under these license agreements, the Company is generally required to make upfront payments and additional payments upon the achievement of milestones and/or royalties on future sales of products until the later of the expiration of the applicable patent or the applicable last date of market exclusivity after the first commercial sale, on a country-by-country basis.

No amounts have been expended under these agreements during the years ended December 31, 2013 or 2012. For products currently in development, future potential milestone payments based on product development are $10.0 million as of December 31, 2013. For all other products, future potential milestone payments related to development milestones and commercialization milestones totaled $84.1 million as of December 31, 2013. There are no minimum royalties required under any of the license agreements. The Company is unable to estimate with certainty the timing on when these milestone payments will occur as these payments are dependent upon the progress of the Company’s product development programs.

Legal Proceedings

From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. The Company is not aware of any such proceedings or claims that it believes will have, individually or in aggregate, a material adverse effect on its business, financial condition or results of operations.

Joint Venture

12 Months Ended

Dec. 31, 2013

Joint Venture

7. Joint Venture

The Company entered into an agreement to form a joint venture company with Zhejiang Medicine Co., Ltd. and Beijing Make-Friend Medicine Technology Co., Ltd. effective September 27, 2011. The joint venture agreement provides for the joint venture company, Zhejiang Sunmy Bio-Medical Co., Ltd. (“Zhejiang Sunmy”), to develop and commercialize MN-221 in China and pursue additional compounds to develop. A sublicense agreement would be required under which Zhejiang Sunmy would license MN-221 from the Company and, as of the date of this filing, no such sublicense agreement has been entered into. In accordance with the joint venture agreement, in March 2012 the Company paid $680,000 for a 30% interest in Zhejiang Sunmy. The other parties to the joint venture agreement provided funding for their combined 70% interest. Zhejiang Sunmy is a variable interest entity for which the Company is not the primary beneficiary as the Company does not have a majority of the board seats and does not have power to direct or significantly influence the actions of the entity. The activities of Zhejiang Sunmy are accounted for under the equity method whereby the Company absorbs any loss or income generated by Zhejiang Sunmy according to the Company’s percentage ownership. At December 31, 2013, the investment is reflected as a long-term asset on the Company’s consolidated balance sheet which represents the investment in Zhejiang Sunmy, net of the Company’s portion of any generated loss or income.

Stock-based Compensation

12 Months Ended

Dec. 31, 2013

Stock-based Compensation

8. Stock-based Compensation

Stock Incentive Plans

In June 2013, the Company adopted the 2013 Equity Incentive Plan, or 2013 Plan, under which the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The 2013 Plan is the successor to the Company’s Amended and Restated 2004 Stock Incentive Plan, or 2004 Plan, which was in turn the successor to the Company’s 2000 General Stock Incentive Plan, or 2000 Plan (together, the Prior Plans). A total of 2,500,000 shares of common stock were initially reserved for issuance under the 2013 Plan, plus “returning shares” that may become available from time to time. “Returning shares” are shares that are subject to outstanding awards granted under the 2004 Plan that expire or terminate prior to exercise or settlement, are forfeited because of the failure to vest, are repurchased, or are withheld to satisfy tax withholding or purchase price obligations in connection with such awards. Although the Company no longer grants equity awards under the Prior Plans, all outstanding stock awards granted under the Prior Plans will continue to be subject to the terms and conditions as set forth in the agreements evidencing such stock awards and the terms of the Prior Plans, as applicable. As of December 31, 2013, 2,612,751 options remain available for future grant under the 2013 Plan.

Stock Options

Options granted under the 2013 Plan and Prior Plans have terms of ten years from the date of grant and generally vest over a three or four year period.

The exercise price of all options granted during the years ended December 31, 2013 and 2012 was equal to the market value of the Company’s common stock on the date of grant.

A summary of stock option activity and related information as of December 31, 2013 is as follows:


	Number of Option Shares			Weighted Average Exercise Price		Weighted Average Contractual Life		Aggregate Intrinsic Value
Outstanding at January 1, 2013		3,328,981		$	4.92
Granted		1,608,000		$	3.42
Exercised		(79,462	)	$	2.44
Cancelled		(1,640,476	)	$	3.29

Outstanding at December 31, 2013		3,217,043		$	5.06		7.0	$	144

Exercisable at December 31, 2013		2,196,688		$	6.09		5.8	$	144

The aggregate intrinsic value of options exercised during 2013 and 2012 was $63,704 and $61,620, respectively. During the year ended December 31, 2013, there were 79,462 stock options exercised, from which proceeds of $0.2 million was received. During the years ended December 31, 2013 and 2012, options to purchase 1,608,000 and 750,000 shares of common stock, respectively, were granted.

Employee Stock Purchase Plan

Under the Company’s 2007 Employee Stock Purchase Plan, or ESPP, 300,000 shares of common stock were originally reserved for issuance. In addition, the shares reserved automatically increase each year by a number equal to the lesser of: (i) 15,000 shares; (ii) 1% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year; or (iii) such lesser amount as determined by the Board. The ESPP permits full-time employees to purchase common stock through payroll deductions (which cannot exceed 15% of each employee’s compensation) at the lower of 85% of fair market value at the beginning of the offering period or the end of each six-month offering period.

For the year ended December 31, 2013, an aggregate of 30,251 shares were issued under the ESPP, leaving 234,327 shares available for future issuance.

Compensation Expense

The estimated fair value of each stock option award was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions for stock option grants:


	Year Ended December 31,
	2013			2012
Stock Options
Risk-free interest rate		1.02	%		0.67	%
Expected volatility of common stock		84.80	%		83.26	%
Dividend yield		0.00	%		0.00	%
Expected option term (in years)		5.68			5.31

The estimated fair value of employee stock purchase rights under the Company’s ESPP was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions for stock option grants:


	Year Ended December 31,
	2013			2012
Employee Stock Purchase Plan
Risk-free interest rate		0.15	%		0.30	%
Expected volatility of common stock		89.66	%		79.50	%
Dividend yield		0.00	%		0.00	%
Expected option term (in years)		0.5			0.5

The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected term of employee stock options. The expected volatility is based on the historical volatility of the Company’s common stock. The Company has not paid nor does the Company anticipate paying dividends on its common stock in the foreseeable future. The expected term of employee stock options is based on the simplified method as provided by the authoritative guidance on stock compensation, as the historical stock option exercise experience does not provide a reasonable basis to estimate the expected term.

The weighted-average fair value of each stock option granted during the years ended December 31, 2013 and 2012, estimated as of the grant date using the Black-Scholes option valuation model, was $2.37 per option and $1.33 per option, respectively.

Stock-based compensation expense for stock option awards and ESPP shares are reflected in total operating expense for each respective year. For the years ended December 31, 2013 and 2012, stock-based compensation expense related to stock options and the ESPP was $1.2 million and $0.7 million, respectively, and was recorded as a component of general and administrative expense ($0.8 million and $0.4 million, respectively) and research and development expense ($0.4 million and $0.3 million, respectively).

As of December 31, 2013, there was $2.0 million of unamortized compensation cost related to unvested stock option awards which is expected to be recognized over a remaining weighted-average vesting period of 1.7 years, on a straight-line basis.

Stockholders' Equity

12 Months Ended

Dec. 31, 2013

Stockholders' Equity

9. Stockholders’ Equity

Kissei Stock Purchase

In October 2011, pursuant to a stock purchase agreement by and between the Company and Kissei Pharmaceutical Co., Ltd., or Kissei, Kissei purchased (i) an aggregate of 800,000 shares of the Company’s common stock, par value $0.001 per share at a price of $2.50 per share, and (ii) 220,000 shares of the Company’s Series B Convertible Preferred Stock, par value $0.01 per share, at a price of $25.00 per share. In October 2011 the Company received gross proceeds of $7.5 million related to this purchase agreement. The purchase agreement contains a standstill agreement from Kissei that terminates if Kissei beneficially owns less than three percent of the Company’s outstanding voting stock. Each share of the Series B Preferred Stock is convertible into 10 shares of common stock. The Series B Preferred ranks pari passu (on an as-if-converted-to-common-stock basis) with the common stock in liquidation and dividend rights. The holders of the Series B Preferred do not have voting rights, however, the consent of holders of a majority of the outstanding Series B Preferred is required for certain actions.

Common Stock Purchase Agreement

On August 20, 2012, the Company entered into a common stock purchase agreement with Aspire pursuant to which the Company could elect sell to Aspire, and Aspire would be obligated to purchase, up to an aggregate of $20 million of common stock over the two-year term of the agreement including $1.0 million in common stock purchased by Aspire in connection with execution of the agreement. The common stock purchase agreement with Aspire was terminated on October 17, 2013, and as of such date, the Company had completed sales to Aspire totaling 2,504,532 shares of common stock at prices ranging from $1.60 to $3.82 per share, generating gross proceeds of $5.4 million.

At-The-Market Issuance Sales Agreements

On April 17, 2013, the Company entered into an at-the-market equity distribution agreement with Macquarie Capital (USA) Inc., or MCUSA, pursuant to which the Company could sell common stock through MCUSA from time to time up to an aggregate offering price of $6.0 million. As of July 25, 2013, the Company had completed all available sales to MCUSA under this agreement, generating gross and net proceeds of $6.0 million and $5.5 million, respectively, on sales of 1,936,237 shares of common stock at prices ranging from $2.44 to $4.10 per share.

On October 16, 2013, the Company entered into a second at-the-market equity distribution agreement with MCUSA pursuant to which the Company may sell common stock through MCUSA from time to time up to an aggregate offering price of $10.0 million. Under the terms of this agreement, unless otherwise mutually agreed, no daily sale of an amount of shares of the Company’s common stock is to exceed the lower of $50,000 or 10% of the lower of the 5-day or 3-month average daily traded value of the Company’s common stock on NASDAQ (unless 10% of the lower of the 5-day or 3-month average daily traded value of the Company’s common stock on the JASDAQ Market of the Tokyo Stock Exchange (“TSE”) is greater, in which case the value from the TSE will be used) as of the date of the applicable issuance notice. The price per share is not to be less than the greater of $1.29 or the last available closing price of a share of the Company’s common stock on NASDAQ. MCUSA agreed to use its commercially reasonable efforts consistent with its customary trading and sales practices and applicable laws, rules and regulations to sell shares of the Company’s common stock and is to sell such shares by any method permitted by law deemed to be “at the market.” The Company agreed to pay MCUSA an aggregate commission rate of 7.0% of the gross proceeds of any common stock sold under this agreement. MCUSA is under no obligation to purchase shares pursuant to this agreement and there are no assurances that MCUSA will be successful in selling shares. Proceeds from sales of common stock will depend on the number of shares of common stock sold to MCUSA and the per share purchase price of each transaction. The agreement with MCUSA provides both MCUSA and the Company the right to terminate the agreement in our their discretion upon giving five business days written notice. As of December 31, 2013, the Company has generated gross and net proceeds of $0.27 million and $0.25 million, respectively, under this agreement on sales of 117,500 shares of the Company’s common stock at prices ranging from $2.15 to $2.58 per share. Between October 16, 2013 and the date of this report, the Company has generated gross and net proceeds of $3.5 million and $3.3 million, respectively, on the sale of 1,607,500 shares of the Company’s common stock under the at-the-market equity distribution agreement with MCUSA, including gross and net proceeds of $3.2 million and $3.0 million, respectively, on the sale of 1,490,000 shares of common stock subsequent to December 31, 2013.

Warrant for Services

On August 22, 2012, the Company issued a warrant in exchange for investor relations services to purchase up to 130,000 of common stock of the Company at a price of $1.88 per share, the closing price of the Company’s common stock on that date. The warrant contained provisions whereby it became exercisable for a specified number of shares of common stock as a result of the stock achieving certain share price targets within a 15-month period beginning on August 22, 2012. As of December 31, 2013, the warrant was exercisable for 15,000 shares, and no further shares will vest. The warrant expires five years from the date of issuance. The warrant was valued at its fair value of approximately $100,000 on August 22, 2012, is classified as equity and was amortized over the one-year period beginning August 22, 2012.

Securities Purchase Agreement

On May 9, 2013, the Company entered into a Securities Purchase Agreement with certain accredited investors (the “Purchase Agreement”) pursuant to which the Company agreed to sell to the investors 1,158,730 shares of the Company’s common stock at a price of $3.15 per share and warrants to purchase an aggregate of 869,047 shares of the Company’s common stock with an exercise price of $3.15 per share (the “Private Placement”). The Private Placement closed on May 14, 2013. The warrants will expire on May 9, 2018 and may be exercised for cash or, if the current market price of common stock of the Company is greater than the per share exercise price, by surrender of a portion of the warrant in a cashless exercise. The aggregate purchase price for the shares and the warrants sold in the Private Placement was $3.7 million and associated expenses incurred were $0.3 million.

In connection with the purchase by one investor of 158,730 shares of common stock and a warrant to purchase 119,047 shares of common stock, on May 29, 2013 the investor provided $51,389 additional consideration for the shares and the warrant, and the Company entered into an amendment to the warrant with the investor to reflect an exercise price of $3.38 per share.

The net proceeds for the shares and the warrants sold in the Private Placement of $3.4 million were allocated based on the relative fair value of each instrument. The fair value of the shares was based on the closing price of the Company’s common stock on May 9, 2013, and the fair value of the warrants based on a Black-Scholes valuation model.

Common Stock Reserved for Future Issuance

The following table summarizes common stock reserved for future issuance at December 31, 2013:


Common Stock reserved for issuance upon conversion of Series B Convertible Preferred Stock			2,200,000
Common Stock reserved for issuance under the ESPP			234,327
Common stock reserved for issuance upon exercise of warrants outstanding			3,761,067
Common stock reserved for issuance upon exercise of options outstanding (under the 2000 Plan, 2004 Plan and 2013 Plan)			3,217,043
Common stock reserved for future equity awards (under the 2013 Plan)			2,612,751

			12,025,188

Treasury Stock

During 2013 the Company determined that it had not been accounting for the resale of treasury stock to employees through the Company’s ESSP correctly. The Company historically recorded the cash proceeds from the resale of treasury stock as a reduction to treasury stock. The Company was not properly accounting for the difference between the price per share the treasury stock was resold for and the price per share it was originally paid by the Company to purchase the shares. Based on a quantitative and qualitative analysis, the Company determined the error to be immaterial to the consolidated balance sheets and the consolidated statements of stockholders’ equity and the error did not impact the consolidated statements of operations or cash flows. To correct this error, the Company has decreased the opening balance of treasury stock and increased the balance of the accumulated deficit at December 31, 2011 in the statement of stockholders’ equity by $760,690 and corrected the resale activity in 2012 resulting in a decrease in treasury stock and an increase in accumulated deficit of $325,691 at December 31, 2012.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Income Taxes

12 Months Ended

Dec. 31, 2013

Income Taxes

10. Income Taxes

A reconciliation of income (loss) before income taxes for domestic and foreign locations for the years ended December 31, 2013 and 2012 is as follows:


	Year Ended December 31,
	2013			2012
United States	$	(4,048,522	)	$	(10,986,343	)
Foreign		24,029			36,173

Loss before income taxes	$	(4,024,493	)	$	(10,950,170	)

A reconciliation of income tax expense for the years ended December 31, 2013 and 2012 is as follows:


	Year Ended December 31,
Current:	2013		2012
Federal	$	—	$	—
State		—		—
Foreign		4,035		11,144

Total current income tax expense		4,035		11,144

Deferred:
Federal		—		—
State		—		—
Foreign		—		—

Total deferred income tax expense		—		—

Total income tax expense	$	4,035	$	11,144

The significant components of deferred income taxes at December 31, 2013 and 2012 are as follows:


	Year Ended December 31,
Deferred tax assets:	2013			2012
Net operating loss carryforwards	$	84,537,000		$	83,092,000
Capitalized licenses		1,576,000			1,822,000
Research tax credits		7,448,000			7,145,000
Stock options		1,763,000			1,861,000
Other, net		1,454,000			1,554,000

Total deferred tax assets		96,778,000			95,474,000

Deferred tax liabilities
In process R&D		(1,956,000	)		(1,956,000	)

Total deferred tax liabilities		(1,956,000	)		(1,956,000	)

Net deferred tax assets		94,822,000			93,518,000
Valuation allowance		(96,778,000	)		(95,474,000	)

Net deferred tax liability	$	(1,956,000	)	$	(1,956,000	)

The Company has established a valuation allowance against net deferred tax assets due to the uncertainty that such assets will be realized. The Company periodically evaluates the recoverability of the deferred tax assets. At such time as it is determined that it is more likely than not that deferred tax assets will be realizable, the valuation allowance will be reduced.

At December 31, 2013, the Company has federal and California net operating losses, or NOL, carryforwards of approximately $207.7 million and $206.6 million, respectively. The federal NOL carryforwards begin to expire in 2020, and the California NOL carryforwards continue to expire in 2014. The Company expects that $108.2 million in California NOL carryforwards will expire by 2017 and the remaining $98.4 million in California NOL carryforwards will begin to expire in 2028. At December 31, 2013, the Company also had federal and California research tax credit carryforwards of approximately $6.5 million and $1.5 million, respectively. The federal research tax credit carryforwards begin to expire in 2024, and the California research tax credit carryforward does not expire and can be carried forward indefinitely until utilized. At December 31, 2013, the Company has both federal and California capital loss carryovers of approximately $1.7 million. The federal and California capital loss carryovers expire in 2015.

The above NOL carryforward and the research tax credit carryforwards are subject to an annual limitation under Section 382 and 383 of the Internal Revenue Code of 1986, and similar state provisions due to ownership change limitations that have occurred which will limit the amount of NOL and tax credit carryforwards that can be utilized to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section 382 and 383, results from transactions increasing ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percentage points over a three-year period. The Company has not completed an IRC Section 382/383 analysis since 2011 regarding the limitation of net operating loss and research and development credit carryforwards. There is a risk that additional changes in ownership have occurred since the completion of the Company’s analysis, which was through December 2011. If a change in ownership were to have occurred, additional NOL and tax credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, related to the Company’s operations in the U.S. will not impact the Company’s effective tax rate.

A reconciliation of the federal statutory income tax rate to the Company’s effective income tax rate is as follows:


	Year Ended December 31,
	2013			2012
Federal statutory income tax rate		35.0	%		35.0	%
State income taxes, net of federal benefit		3.6			5.8
Tax credits		7.5			—
Change in valuation allowance		(63.7	)		(28.3	)
Permanent differences		(0.3	)		(0.1	)
Stock compensation		20.0			(12.6	)
Other		(2.2	)		0.1

Provision for income taxes		(0.1	)%		(0.1	)%

The Company files income tax returns in the United States, California and foreign jurisdictions. Due to the Company’s losses incurred, the Company is essentially subject to income tax examination by tax authorities from inception to date. The Company’s policy is to recognize interest expense and penalties related to income tax matters as tax expense. At December 31, 2013, there are no unrecognized tax benefits, and there are not significant accruals for interest related to unrecognized tax benefits or tax penalties.

In preparing the 2013 financial statement footnote disclosures, the Company determined that the December 31, 2012 deferred tax asset for stock based compensation included an error and was understated by $1.3 million, and the valuation allowance was understated by the same amount. Also during 2013, the Company determined that it did not record a deferred tax asset related to the Kissei deferred revenue as of December 31, 2012. As a result, the December 31, 2012 other deferred tax asset was understated by $0.7 million, and the deferred tax asset for net operating losses was overstated by the same amount. Accordingly, the 2012 amounts have been changed for the purposes of presentation within the above table. These changes in the disclosed deferred tax assets and valuation allowance did not impact the consolidated balance sheets or the consolidated statements of stockholders’ equity, operations, or cash flows as the Company is in a net loss position with a full valuation allowance on their deferred tax assets.

Employee Savings Plan	12 Months Ended
Employee Savings Plan	Dec. 31, 2013
Employee Savings Plan	11. Employee Savings Plan The Company has an employee savings plan available to substantially all employees. Under the plan, an employee may elect salary reductions which are contributed to the plan. The plan provides for discretionary contributions by us, which totaled $87,710 and $96,415 for the years ended December 31, 2013 and 2012.

Quarterly Financial Data

12 Months Ended

Dec. 31, 2013

Quarterly Financial Data

12. Quarterly Financial Data (Unaudited)

The following table presents certain quarterly financial data for eight consecutive quarters ended December 31, 2013. The unaudited quarterly information has been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, includes all adjustments, necessary for a fair presentation of this data (in thousands, except per share data). As the shares of Series B Convertible Preferred Stock participate equally with the common shares upon payment of dividends, the two-class method is not applicable in the calculation of earnings per share for the fourth quarter of 2013 when net income was recorded.


	Year Ended December 31, 2013
	1st Quarter			2nd Quarter			3rd Quarter			4th Quarter
Selected quarterly financial data:
Revenues	$	3		$	—		$	—		$	6,000
Total operating expenses		2,421			2,788			2,242			2,573
Net income (loss)		(2,419	)		(2,786	)		(2,237	)		3,413
Net income (loss) applicable to common stockholders		(2,419	)		(2,786	)		(2,237	)		3,413
Basic net income (loss) per common share(1)		(0.14	)		(0.14	)		(0.10	)		0.15
Diluted net income (loss) per common share(1)		(0.14	)		(0.14	)		(0.10	)		0.14


	Year Ended December 31, 2012
	1st Quarter			2nd Quarter			3rd Quarter			4th Quarter
Selected quarterly financial data:
Revenues	$	191		$	494		$	84		$	34
Total operating expenses		4,064			2,781			2,446			2,455
Net loss		(3,867	)		(2,281	)		(2,379	)		(2,434	)
Net loss applicable to common stockholders		(3,867	)		(2,281	)		(2,379	)		(2,434	)
Basic and diluted net loss per common share(1)		(0.24	)		(0.14	)		(0.14	)		(0.14	)

(1)	Income and loss per share is computed independently for each of the quarters presented. The sum of the quarterly net income and loss per share will not necessarily equal the total for the year.

Subsequent Events

12 Months Ended

Dec. 31, 2013

Subsequent Events

13. Subsequent Events

On January 10, 2014, the Company received a payment of $6.0 million from Genzyme in relation to the development milestone earned in December 2013 as described in Note 2 of the financial statements.

On March 10, 2014, the Company announced that it entered into an agreement with Research Foundation for Mental Hygiene, Inc. to supply Ibudilast (MN-166) for their clinical study of Ibudilast in marijuana-dependent subjects. The study will be led by investigators from Columbia University.

Subsequent to December 31, 2013 through the date of this report, the Company generated gross and net proceeds of $3.2 million and $3.0 million, respectively, on the sale of 1,490,000 shares of common stock under the second at-the-market equity distribution agreement with MCUSA.

Organization and Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2013

Principles of Consolidation

Principles of Consolidation

Segment Reporting

Segment Reporting

The Company operates in a single industry segment – the discovery and development of small molecule therapeutics.

Use of Estimates

Use of Estimates

Cash and Cash Equivalents

Cash and Cash Equivalents

Concentrations and Credit Risk

Concentrations and Credit Risk

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Goodwill and Purchased Intangibles

Goodwill and Purchased Intangibles

Research, Development and Patents

Research, Development and Patents

Stock-Based Compensation

Stock-Based Compensation

Net Loss Per Share

Net Loss Per Share

Potentially dilutive outstanding securities excluded from diluted net loss per common share because of their anti-dilutive effect:


	December 31,
	2013		2012
Convertible preferred stock, as converted		2,200,000		2,200,000
Stock options		3,217,043		3,328,981
Warrants		3,761,067		3,128,686

Total		9,178,110		8,657,667

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Revenue Recognition Policy

Revenue Recognition Policy

Organization and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2013

Securities Excluded from Diluted Net Loss per Common Share

Potentially dilutive outstanding securities excluded from diluted net loss per common share because of their anti-dilutive effect:


	December 31,
	2013		2012
Convertible preferred stock, as converted		2,200,000		2,200,000
Stock options		3,217,043		3,328,981
Warrants		3,761,067		3,128,686

Total		9,178,110		8,657,667

Balance Sheet Details (Tables)

12 Months Ended

Dec. 31, 2013

Property and Equipment Net

Property and equipment, net, consist of the following:


	December 31,
	2013			2012
Leasehold improvements	$	16,854		$	170,386
Furniture and equipment		257,945			351,992
Software		238,808			228,397

		513,607			750,775
Less accumulated depreciation and amortization		(431,193	)		(672,301	)

	$	82,414		$	78,474

Depreciation expense	$	36,655		$	33,507

Accrued Expenses

Accrued expenses consist of the following:


	December 31,
	2013		2012
Research and development costs	$	99,846	$	152,046
Professional services fees		38,208		68,102
Other		102,094		94,504

	$	240,148	$	314,652

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2013

Future Minimum Payments


Years ending December 31:
2014	$	260,213
2015		206,441
2016		167,373
2017		139,608

Total minimum payments	$	773,635

- Definition

Tabular disclosure of a lessee's leasing arrangements including: (1) the basis on which contingent rental payments are determined, (2) the existence and terms of renewal or purchase options and escalation clauses, (3) restrictions imposed by lease arrangements, such as those concerning dividends, additional debt, and further leasing, (4) rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions. Disclosure may also include the specific period used to amortize material leasehold improvements made at the inception of the lease or during the lease term. Additionally, for operating leases having initial or remaining noncancelable lease terms in excess of one year: (a) future minimum rental payments required as of the date of the latest balance sheet presented, in the aggregate and for each of the five succeeding fiscal years, (b) the total of minimum rentals to be received in the future under noncancelable subleases as of the date of the latest balance sheet presented, and (c) for all operating leases, rental expense for each period for which an income statement is presented, with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included.

+ References + Details

Stock-based Compensation (Tables)

12 Months Ended

Dec. 31, 2013

Summary of Stock Option Activity and Related Information

A summary of stock option activity and related information as of December 31, 2013 is as follows:


	Number of Option Shares			Weighted Average Exercise Price		Weighted Average Contractual Life		Aggregate Intrinsic Value
Outstanding at January 1, 2013		3,328,981		$	4.92
Granted		1,608,000		$	3.42
Exercised		(79,462	)	$	2.44
Cancelled		(1,640,476	)	$	3.29

Outstanding at December 31, 2013		3,217,043		$	5.06		7.0	$	144

Exercisable at December 31, 2013		2,196,688		$	6.09		5.8	$	144

Stock Options

Weighted-Average Assumptions for Stock Option


	Year Ended December 31,
	2013			2012
Stock Options
Risk-free interest rate		1.02	%		0.67	%
Expected volatility of common stock		84.80	%		83.26	%
Dividend yield		0.00	%		0.00	%
Expected option term (in years)		5.68			5.31

Employee Stock Purchase Plan

Weighted-Average Assumptions for Stock Option


	Year Ended December 31,
	2013			2012
Employee Stock Purchase Plan
Risk-free interest rate		0.15	%		0.30	%
Expected volatility of common stock		89.66	%		79.50	%
Dividend yield		0.00	%		0.00	%
Expected option term (in years)		0.5			0.5

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2013

Common Stock Reserved for Future Issuance

The following table summarizes common stock reserved for future issuance at December 31, 2013:


Common Stock reserved for issuance upon conversion of Series B Convertible Preferred Stock			2,200,000
Common Stock reserved for issuance under the ESPP			234,327
Common stock reserved for issuance upon exercise of warrants outstanding			3,761,067
Common stock reserved for issuance upon exercise of options outstanding (under the 2000 Plan, 2004 Plan and 2013 Plan)			3,217,043
Common stock reserved for future equity awards (under the 2013 Plan)			2,612,751

			12,025,188

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2013

Reconciliation of Income (Loss) before Income Taxes for Domestic and Foreign Locations

A reconciliation of income (loss) before income taxes for domestic and foreign locations for the years ended December 31, 2013 and 2012 is as follows:


	Year Ended December 31,
	2013			2012
United States	$	(4,048,522	)	$	(10,986,343	)
Foreign		24,029			36,173

Loss before income taxes	$	(4,024,493	)	$	(10,950,170	)

Reconciliation of Income Tax Expense

A reconciliation of income tax expense for the years ended December 31, 2013 and 2012 is as follows:


	Year Ended December 31,
Current:	2013		2012
Federal	$	—	$	—
State		—		—
Foreign		4,035		11,144

Total current income tax expense		4,035		11,144

Deferred:
Federal		—		—
State		—		—
Foreign		—		—

Total deferred income tax expense		—		—

Total income tax expense	$	4,035	$	11,144

Components of Deferred IncomeTaxes

The significant components of deferred income taxes at December 31, 2013 and 2012 are as follows:


	Year Ended December 31,
Deferred tax assets:	2013			2012
Net operating loss carryforwards	$	84,537,000		$	83,092,000
Capitalized licenses		1,576,000			1,822,000
Research tax credits		7,448,000			7,145,000
Stock options		1,763,000			1,861,000
Other, net		1,454,000			1,554,000

Total deferred tax assets		96,778,000			95,474,000

Deferred tax liabilities
In process R&D		(1,956,000	)		(1,956,000	)

Total deferred tax liabilities		(1,956,000	)		(1,956,000	)

Net deferred tax assets		94,822,000			93,518,000
Valuation allowance		(96,778,000	)		(95,474,000	)

Net deferred tax liability	$	(1,956,000	)	$	(1,956,000	)

Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate

A reconciliation of the federal statutory income tax rate to the Company’s effective income tax rate is as follows:


	Year Ended December 31,
	2013			2012
Federal statutory income tax rate		35.0	%		35.0	%
State income taxes, net of federal benefit		3.6			5.8
Tax credits		7.5			—
Change in valuation allowance		(63.7	)		(28.3	)
Permanent differences		(0.3	)		(0.1	)
Stock compensation		20.0			(12.6	)
Other		(2.2	)		0.1

Provision for income taxes		(0.1	)%		(0.1	)%

Quarterly Financial Data (Tables)

12 Months Ended

Dec. 31, 2013

Summarized Quarterly Data


	Year Ended December 31, 2013
	1st Quarter			2nd Quarter			3rd Quarter			4th Quarter
Selected quarterly financial data:
Revenues	$	3		$	—		$	—		$	6,000
Total operating expenses		2,421			2,788			2,242			2,573
Net income (loss)		(2,419	)		(2,786	)		(2,237	)		3,413
Net income (loss) applicable to common stockholders		(2,419	)		(2,786	)		(2,237	)		3,413
Basic net income (loss) per common share(1)		(0.14	)		(0.14	)		(0.10	)		0.15
Diluted net income (loss) per common share(1)		(0.14	)		(0.14	)		(0.10	)		0.14


	Year Ended December 31, 2012
	1st Quarter			2nd Quarter			3rd Quarter			4th Quarter
Selected quarterly financial data:
Revenues	$	191		$	494		$	84		$	34
Total operating expenses		4,064			2,781			2,446			2,455
Net loss		(3,867	)		(2,281	)		(2,379	)		(2,434	)
Net loss applicable to common stockholders		(3,867	)		(2,281	)		(2,379	)		(2,434	)
Basic and diluted net loss per common share(1)		(0.24	)		(0.14	)		(0.14	)		(0.14	)

(1)	Income and loss per share is computed independently for each of the quarters presented. The sum of the quarterly net income and loss per share will not necessarily equal the total for the year.

Organization and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Cash and cash equivalents	$ 6,700,493	$ 4,010,530	$ 15,093,124
Working capital	13,900,000
Cash insured amount	250,000
Research and development	2,700,000	4,500,000
Patent-related expenses	700,000	$ 500,000
Genzyme Agreement
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Milestone revenue	$ 6,000,000
Minimum
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Stock option, vesting period	3 years
Maximum
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Stock option, vesting period	4 years

Securities Excluded from Diluted Net Loss Per Common Share (Detail) - shares	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	9,178,110	8,657,667
Convertible preferred stock, as converted
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	2,200,000	2,200,000
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	3,217,043	3,328,981
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	3,761,067	3,128,686

Revenue Recognition - Additional Information (Detail) - USD ($)	1 Months Ended		12 Months Ended
	Oct. 31, 2011	Dec. 31, 2005	Dec. 31, 2013	Dec. 31, 2012
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
License revenue			$ 6,000,000
Receivable			6,008,553
Deferred revenue related to research and development services	$ 2,500,000
Revenue relating to research and development services	$ 2,500,000		3,000.0	$ 800,000
Genzyme Agreement
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Payments to acquire intellectual property programs and other assets		$ 12,000,000
License revenue			6,000,000
Receivable			$ 6,000,000

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions	Dec. 31, 2013	Dec. 31, 2012
Fair Value Measurements [Line Items]
Cash equivalents, including money market accounts	$ 6.0	$ 3.9

Property and Equipment Net (Detail) - USD ($)	12 Months Ended
Property and Equipment Net (Detail) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant, and Equipment Disclosure [Line Items]
Leasehold improvements	$ 16,854	$ 170,386
Furniture and equipment	257,945	351,992
Software	238,808	228,397
Property, Plant and Equipment, Gross, Total	513,607	750,775
Less accumulated depreciation and amortization	(431,193)	(672,301)
Property and equipment, net	82,414	78,474
Depreciation expense	$ 36,655	$ 33,507

Accrued Expenses (Detail) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Accrued Expenses [Line Items]
Research and development costs	$ 99,846	$ 152,046
Professional services fees	38,208	68,102
Other	102,094	94,504
Accrued Liabilities, Current, Total	$ 240,148	$ 314,652

Related Party Transactions - Additional Information (Detail) - USD ($)	1 Months Ended		12 Months Ended
	May 09, 2013	Oct. 31, 2011	Dec. 31, 2013	Dec. 31, 2012
Related Party Transaction [Line Items]
Revenue relating to research and development services		$ 2,500,000	$ 3,000.0	$ 800,000
Common Stock
Related Party Transaction [Line Items]
Common stock purchased, shares		800,000	4,860,939
Warrant issued to purchase Common shares				1,219,696
Private Placement \| Common Stock
Related Party Transaction [Line Items]
Common stock purchased, shares	1,158,730
Private Placement \| Warrants
Related Party Transaction [Line Items]
Warrant issued to purchase Common shares	869,047

Commitments and Contingencies - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Loss Contingencies [Line Items]
Operating lease, initial terms	4 years 9 months
Operating lease expiration period	2017-11
Rent expense	$ 259,690	$ 286,762
Deferred rent	9,889	0
Research and development expense	2,700,000	4,500,000
Licensing Agreements
Loss Contingencies [Line Items]
Research and development expense	0	$ 0
Product Development
Loss Contingencies [Line Items]
Future potential milestone payments	10,000,000
Development Milestone
Loss Contingencies [Line Items]
Future potential milestone payments	84,100,000
Commercialization Milestone
Loss Contingencies [Line Items]
Future potential milestone payments	$ 84,100,000

Estimated Future Annual Minimum Lease Payments under Non-Cancelable Building and Copier Leases (Detail)	Dec. 31, 2013 USD ($)
Operating Leased Assets [Line Items]
2014	$ 260,213
2015	206,441
2016	167,373
2017	139,608
Total minimum payments	$ 773,635

Joint Venture - Additional Information (Detail)	1 Months Ended
Joint Venture - Additional Information (Detail)	Mar. 31, 2012 USD ($)
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Investment in China joint venture	$ 680,000
Investment in China joint venture, percentage	30.00%
Other parties investment in China joint venture, percentage	70.00%

Stock-Based Compensation - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2007	Jun. 30, 2013
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Common Stock reserved for future issuance	12,025,188
Options granted expiration term	10 years
Aggregate intrinsic value	$ 63,704,000,000	$ 61,620,000,000
Stock options exercised	79,462
Proceed from stock options exercised	$ 200,000
Common stock options, granted	1,608,000	750,000
Percentage of employee compensation for purchase of common stock under ESPP			Cannot exceed 15%
Common stock fair market value, percentage			85.00%
Employee stock purchase plan offering period			6 months
Shares issued under ESPP	30,251
Shares available for future issuance	234,327
Weighted-average fair value, per option	$ 2.37	$ 1.33
Stock-based compensation expense	$ 1,216,444	$ 709,650
Unamortized compensation cost	$ 2,000,000
Unamortized compensation cost, vesting period	1 year 8 months 12 days
Employee Stock Purchase Plan
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Common Stock reserved for future issuance	234,327		300,000
Shares reserved, description			Shares reserved automatically increase each year by a number equal to the lesser of (i) 15,000 shares; (ii) 1% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year; or
General and administrative expenses
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Stock-based compensation expense	$ 800,000	400,000
Research and development costs
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Stock-based compensation expense	$ 400,000	$ 300,000
2013 Plan
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Common Stock reserved for future issuance				2,500,000
Stock option available for future grant	2,612,751
Minimum
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Stock option, vesting period	3 years
Maximum
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Stock option, vesting period	4 years

Changes in Stock Options Outstanding (Detail) - USD ($)	12 Months Ended
Changes in Stock Options Outstanding (Detail) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Number of Option Shares
Stock Options, Beginning Balance	3,328,981
Stock Options, Granted	1,608,000	750,000
Stock Options, Exercised	(79,462)
Stock Options, Cancelled	(1,640,476)
Stock Options, Ending Balance	3,217,043	3,328,981
Stock Options, Exercisable at December 31, 2013	2,196,688
Weighted Average Exercise Price
Weighted Average Exercise Price, Beginning Balance	$ 4.92
Weighted Average Exercise Price, Granted	3.42
Weighted Average Exercise Price, Exercised	2.44
Weighted Average Exercise Price, Cancelled	3.29
Weighted Average Exercise Price, Ending Balance	5.06	$ 4.92
Weighted Average Exercise Price, Exercisable at December 31, 2013	$ 6.09
Weighted Average Contractual Life
Weighted Average Contractual Life, Ending balance	7 years
Weighted Average Contractual Life, Exercisable at December 31, 2013	5 years 9 months 18 days
Aggregate Intrinsic Value
Aggregate Intrinsic Value, Ending balance	$ 144
Aggregate Intrinsic Value, Exercisable at December 31, 2013	$ 144

Weighted-Average Assumptions for Stock Option (Detail)	12 Months Ended
Weighted-Average Assumptions for Stock Option (Detail)	Dec. 31, 2013	Dec. 31, 2012
Stock Options
Weighted-average assumptions for stock options and ESPP
Risk-free interest rate	1.02%	0.67%
Expected volatility of common stock	84.80%	83.26%
Dividend yield	0.00%	0.00%
Expected option term (in years)	5 years 8 months 5 days	5 years 3 months 22 days
Employee Stock Purchase Plan
Weighted-average assumptions for stock options and ESPP
Risk-free interest rate	0.15%	0.30%
Expected volatility of common stock	89.66%	79.50%
Dividend yield	0.00%	0.00%
Expected option term (in years)	6 months	6 months

Stockholders Equity - Additional Information (Detail)	1 Months Ended						2 Months Ended	12 Months Ended
Stockholders Equity - Additional Information (Detail)	Oct. 16, 2013 USD ($) $ / shares	Jul. 25, 2013 USD ($) $ / shares shares	May 29, 2013 USD ($) $ / Warrants shares	May 09, 2013 USD ($) $ / shares $ / Warrants shares	Aug. 31, 2012 USD ($)	Oct. 31, 2011 USD ($) $ / shares shares	Dec. 31, 2013 USD ($) $ / shares shares	Dec. 31, 2013 USD ($) $ / shares shares	Dec. 31, 2012 USD ($) $ / shares	Dec. 31, 2011 USD ($)	Apr. 17, 2013 USD ($)	Aug. 22, 2012 USD ($) $ / Warrants shares	Mar. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, par value \| $ / shares							$ 0.001	$ 0.001	$ 0.001
Series B Convertible Preferred Stock par value \| $ / shares							$ 0.01	$ 0.01	$ 0.01
Percentage of outstanding voting stock													30.00%
Stock purchased, amount								$ 12,687,125
Warrant issued to purchase Common shares \| shares												130,000
Common share exercise price \| $ / Warrants												1.88
Warrant, exercisable period					15 months
Warrant, exercisable shares \| shares							15,000	15,000
Warrant, expiration period					5 years
Warrant, fair value												$ 100,000
Warrant, amortization period					1 year
Net Proceeds form issuance of shares and warrants in private placement								$ 3,400,000
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock purchase agreement, shares \| shares						800,000		4,860,939
Shares purchase & equity issuance, per share amount \| $ / shares						$ 2.50
Stock purchased, amount								$ 4,861
Series B Preferred Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares purchase & equity issuance, per share amount \| $ / shares						25.00
Kissei Stock Purchase Agreement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, par value \| $ / shares						0.001
Series B Convertible Preferred Stock par value \| $ / shares						$ 0.01
Gross proceeds						$ 7,500,000
Percentage of outstanding voting stock						3.00%
Series B Preferred stock conversion term						Each share of the Series B Preferred Stock is convertible into 10 shares of common stock.
Series B Preferred Stock, Shares Issued upon Conversion \| shares						10
Kissei Stock Purchase Agreement \| Series B Preferred Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock purchase agreement, shares \| shares						220,000
Purchase Agreement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares purchase & equity issuance, per share amount \| $ / shares				$ 3.15
Warrant issued to purchase Common shares \| shares				869,047
Common share exercise price \| $ / Warrants				3.15
Warrant termination date				May 9, 2018
Aggregate purchase price for shares and warrants under private placements				$ 3,700,000
Cost related to private placement				$ 300,000
Purchase Agreement \| Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock purchase agreement, shares \| shares				1,158,730
Investor
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant issued to purchase Common shares \| shares			119,047
Common share exercise price \| $ / Warrants			3.38
Additional consideration received for shares and warrants			$ 51,389
Investor \| Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock purchase agreement, shares \| shares			158,730
Restatement Adjustment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Decrease in treasury stock									$ 325,691	$ 760,690
Increase in accumulated deficit									$ 325,691	$ 760,690
Aspire Capital Fund Llc \| Kissei Stock Purchase Agreement \| Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock purchase agreement, shares \| shares								2,504,532
Stock purchase agreement, aggregate amount of common stock agreed to be purchased					$ 20,000,000
Stock purchased, amount					$ 1,000,000
Stock purchase agreement, term of agreement					2 years
Stock purchase agreement, proceeds								$ 5,400,000
Aspire Capital Fund Llc \| Minimum \| Kissei Stock Purchase Agreement \| Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares purchase & equity issuance, per share amount \| $ / shares								$ 1.60
Aspire Capital Fund Llc \| Maximum \| Kissei Stock Purchase Agreement \| Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares purchase & equity issuance, per share amount \| $ / shares								$ 3.82
MCUSA
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock purchase agreement, shares \| shares								1,490,000
Common Stock purchase agreement, gross proceeds from sale								$ 3,200,000
Common Stock purchase agreement, net proceeds from sale								$ 3,000,000
MCUSA \| April 17, 2013 At Market Sales Agreement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock purchase agreement, shares \| shares		1,936,237					1,490,000
Stock purchase agreement, aggregate amount of common stock agreed to be purchased											$ 6,000,000
Common Stock purchase agreement, gross proceeds from sale		$ 6,000,000					$ 3.2
Common Stock purchase agreement, net proceeds from sale		$ 5,500,000					$ 3.0
MCUSA \| October 16, 2013 At Market Sales Agreement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock purchase agreement, shares \| shares							1,607,500	117,500
Stock purchase agreement, aggregate amount of common stock agreed to be purchased	$ 10,000,000
Common Stock purchase agreement, gross proceeds from sale							$ 3,500,000	$ 270,000
Common Stock purchase agreement, net proceeds from sale							$ 3,300,000	$ 250,000
Stock Purchase Agreement, maximum amount of sale	$ 50,000
Stock Purchase Agreement, maximum amount of sale terms	10% of the lower of the 5-day or 3-month average daily traded value of the Company's common stock
Sales commission as a percentage of gross proceeds	7.00%
MCUSA \| Minimum \| April 17, 2013 At Market Sales Agreement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares purchase & equity issuance, per share amount \| $ / shares		$ 2.44
MCUSA \| Minimum \| October 16, 2013 At Market Sales Agreement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares purchase & equity issuance, per share amount \| $ / shares	$ 1.29							$ 2.15
MCUSA \| Maximum \| April 17, 2013 At Market Sales Agreement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares purchase & equity issuance, per share amount \| $ / shares		$ 4.10
MCUSA \| Maximum \| October 16, 2013 At Market Sales Agreement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares purchase & equity issuance, per share amount \| $ / shares								$ 2.58

Common Stock Reserved for Future Issuance (Detail) - shares	Dec. 31, 2013	Dec. 31, 2007
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Common Stock reserved for future issuance	12,025,188
Series B Preferred Stock
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Common Stock reserved for future issuance	2,200,000
2000 Plan, 2004 Plan and 2013 Plan
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Common Stock reserved for future issuance	3,217,043
Stock Plan 2013
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Common Stock reserved for future issuance	2,612,751
Warrants
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Common Stock reserved for future issuance	3,761,067
Employee Stock Purchase Plan
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Common Stock reserved for future issuance	234,327	300,000

Reconciliation of Income (Loss) before Income Taxes (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Components Of Earnings Loss Before Income Taxes [Line Items]
United States	$ (4,048,522)	$ (10,986,343)
Foreign	24,029	36,173
Loss before income taxes	$ (4,024,493)	$ (10,950,170)

Reconciliation of Income Tax Expense (Detail) - USD ($)	12 Months Ended
Reconciliation of Income Tax Expense (Detail) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Components Of Income Tax Expense Benefit [Line Items]
Federal
State
Foreign	4,035	11,144
Total current income tax expense	4,035	11,144
Federal
State
Foreign
Total deferred income tax expense
Total income tax expense	$ 4,035	$ 11,144

Deferred Income Taxes (Detail) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:
Net operating loss carryforwards	$ 84,537,000	$ 83,092,000
Capitalized licenses	1,576,000	1,822,000
Research tax credits	7,448,000	7,145,000
Stock options	1,763,000	1,861,000
Other, net	1,454,000	1,554,000
Total deferred tax assets	96,778,000	95,474,000
Deferred tax liabilities
In process R&D	(1,956,000)	(1,956,000)
Total deferred tax liabilities	(1,956,000)	(1,956,000)
Net deferred tax assets	94,822,000	93,518,000
Valuation allowance	(96,778,000)	(95,474,000)
Net deferred tax liability	$ (1,956,000)	$ (1,956,000)

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax [Line Items]
Capital loss carryovers, expiration year	2015
Increase of ownership of certain stockholders or public groups in the stock, percentage	50.00%
Increase of ownership of certain stockholders or public groups in the stock, period	3 years
Deferred tax asset for stock based compensation adjustment	$ 1,763,000	$ 1,861,000
Deferred tax assets valuation allowance adjustment	96,778,000	95,474,000
Deferred tax assets	96,778,000	95,474,000
Other deferred tax assets	1,454,000	$ 1,554,000
Restatement Adjustment
Income Tax [Line Items]
Deferred tax asset for stock based compensation adjustment	(1,300,000)
Deferred tax assets valuation allowance adjustment	(1,300,000)
Other deferred tax assets	(700,000)
Kissei Pharmaceutical Company Limited [Member]
Income Tax [Line Items]
Deferred tax assets	700,000
Federal
Income Tax [Line Items]
Net operating loss carry-forwards	$ 207,700,000
Net operating loss carry forward, expiration year	2020
Research tax credit carry-forwards	$ 6,500,000
Research and Development Credits, expiration period	2024
California
Income Tax [Line Items]
Net operating loss carry-forwards	$ 206,600,000
Net operating loss carry forward, expiration year	2014
Research tax credit carry-forwards	$ 1,500,000
California \| Scenario 3
Income Tax [Line Items]
Net operating loss carry-forwards	$ 108,200,000
Net operating loss carry forward, expiration year	2017
California \| Scenario 4
Income Tax [Line Items]
Net operating loss carry-forwards	$ 98,400,000
Net operating loss carry forward, expiration year	2028
Federal and California
Income Tax [Line Items]
Capital loss carryovers	$ 1,700,000

Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Schedule of Effective Tax Rate Reconciliation [Line Items]
Federal statutory income tax rate	35.00%	35.00%
State income taxes, net of federal benefit	3.60%	5.80%
Tax credits	7.50%
Change in valuation allowance	(63.70%)	(28.30%)
Permanent differences	(0.30%)	(0.10%)
Stock compensation	20.00%	(12.60%)
Other	(2.20%)	0.10%
Provision for income taxes	(0.10%)	(0.10%)

Employee Savings Plan - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Defined Contribution Plan Disclosure [Line Items]
Discretionary contributions to employee savings plan	$ 87,710	$ 96,415

Selected Quarterly Financial Information (Detail) - USD ($)

3 Months Ended

12 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Quarterly Financial Data [Line Items]

Revenues

$ 6,000,000

$ 3,000

$ 34,000

$ 84,000

$ 494,000

$ 191,000

Total operating expenses

2,573,000

$ 2,242,000

$ 2,788,000

2,421,000

2,455,000

2,446,000

2,781,000

4,064,000

$ 10,023,797

$ 11,747,936

Net income (loss)

3,413,000

(2,237,000)

(2,786,000)

(2,419,000)

(2,434,000)

(2,379,000)

(2,281,000)

(3,867,000)

(4,028,528)

(10,961,314)

Net income (loss) applicable to common stockholders

$ 3,413,000

$ (2,237,000)

$ (2,786,000)

$ (2,419,000)

$ (2,434,000)

$ (2,379,000)

$ (2,281,000)

$ (3,867,000)

$ (4,028,528)

$ (10,961,314)

Basic net income (loss) per common share

^[1]

$ 0.15

$ (0.10)

$ (0.14)

Basic and diluted net loss per common share

$ (0.14)

^[1]

$ (0.14)

^[1]

$ (0.14)

^[1]

$ (0.24)

^[1]

$ (0.19)

$ (0.66)

Diluted net income (loss) per common share

^[1]

$ 0.14

$ (0.10)

$ (0.14)

[1]	Income and loss per share is computed independently for each of the quarters presented. The sum of the quarterly net income and loss per share will not necessarily equal the total for the year.

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Subsequent Events - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2013	Jan. 10, 2014
MCUSA
Subsequent Event [Line Items]
Common Stock purchase agreement, gross proceeds from sale	$ 3.2
Common Stock purchase agreement, net proceeds from sale	$ 3.0
Common Stock purchase agreement, shares	1,490,000
Subsequent Event \| Genzyme Agreement
Subsequent Event [Line Items]
Payment received		$ 6.0